Zobrazeno 1 - 10 of 20 pro vyhledávání: '"Galit Rosen"'
2
Akademický článek
Transcription and methylation analyses of preleukemic promyelocytes indicate a dual role for PML/RARA in leukemia initiation
Autor: Coline Gaillard, Taku A. Tokuyasu, Galit Rosen, Jason Sotzen, Adeline Vitaliano-Prunier, Ritu Roy, Emmanuelle Passegué, Hugues de Thé, Maria E. Figueroa, Scott C. Kogan
Publikováno v: Haematologica, Vol 100, Iss 8 (2015)
Acute promyelocytic leukemia is an aggressive malignancy characterized by the accumulation of promyelocytes in the bone marrow. PML/RARA is the primary abnormality implicated in this pathology, but the mechanisms by which this chimeric fusion protein
Externí odkaz: https://doaj.org/article/4e7566ae589c4769b0334a3456f24838
Zobrazit plný text záznamu
6
Anti–Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development
Autor: Andrea Necchi, Thomas Powles, Galit Rosen, Subramanian Hariharan, Andrea B. Apolo
Publikováno v: Clinical Genitourinary Cancer. 16:117-129
INTRODUCTION/BACKGROUND: Immunotherapy with programmed cell death-1/ligand-1 (PD-1/PD-L1) checkpoint inhibitors has expanded a previously limited pool of effective treatment options for patients with metastatic urothelial carcinoma, particularly thos
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::beda10cb8b2823ade2dbb62c65dab239
https://doi.org/10.1016/j.clgc.2017.11.002
Zobrazit plný text záznamu
7
Safety and Efficacy of Menin Inhibition in Patients (Pts) with MLL-Rearranged and NPM1 Mutant Acute Leukemia: A Phase (Ph) 1, First-in-Human Study of SNDX-5613 (AUGMENT 101)
Autor: Manish R. Patel, Martha Arellano, Yifan Huang, Rebecca G. Bagley, Michael L. Meyers, Michael J. Thirman, Ghayas C. Issa, Ibrahim Aldoss, Galit Rosen, Richard Stone, John F. DiPersio, Steve Smith, Eytan M. Stein
Publikováno v: Blood. 138:699-699
Introduction: Translocations involving the MLL gene on chromosome 11q23 result in fusions with ≥10 partner genes that act as drivers in relatively chemotherapy resistant MLL-rearranged (MLLr) leukemias. These chimeric proteins form part of protein
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::000dc27a081dc9ef983ee4af239326c3
https://doi.org/10.1182/blood-2021-146944
Zobrazit plný text záznamu
8
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Autor: Galit Rosen, Andrea B. Apolo, Manish R. Patel, Mathew Taylor, Junyuan Xiong, Michael Gordon, Keun Wook Lee, Manish Agrawal, James L. Gulley, Carolyn D. Britten, Ding Wang, Jeffrey R. Infante, John Allan Ellerton, Alain Ravaud, Luc Dirix, Patrick Schöffski, Raid Aljumaily, Arnold B. Gelb
Publikováno v: Lancet Oncol
Translational Cancer Research
Summary Background The approval of anti-programmed death ligand 1 (PD-L1) and anti-programmed death 1 agents has expanded treatment options for patients with locally advanced or metastatic urothelial carcinoma. Avelumab, a human monoclonal anti-PD-L1
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b17458409e554d7d7e53d1e16ee0c45
https://europepmc.org/articles/PMC7984727/
Zobrazit plný text záznamu
9
Avelumab treatment in metastatic urothelial carcinoma: Association between early response and durable outcomes in the phase Ib JAVELIN Solid Tumor Study
Autor: Vijay Kasturi, James L. Gulley, Juliane Manitz, Andrea B. Apolo, Hao Zhang, Keun-Wook Lee, Galit Rosen, Manish R. Patel, Jeffrey R. Infante
Publikováno v: Journal of Clinical Oncology. 37:429-429
429 Background: Avelumab is a human anti‒PD-L1 IgG1 antibody approved in the US, Canada, and Israel for the treatment of locally advanced or metastatic urothelial carcinoma (mUC) progressed after platinum chemotherapy. In the JAVELIN Solid Tumor st
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a8d13ef8e90ab6375e224e79e80083f1
https://doi.org/10.1200/jco.2019.37.7_suppl.429
Zobrazit plný text záznamu
10
Avelumab treatment in metastatic urothelial carcinoma: Post-hoc analysis of high-risk populations in the phase Ib JAVELIN Solid Tumor Study
Autor: Manish R. Patel, Vijay Kasturi, James L. Gulley, Andrea B. Apolo, John Warth, John Allan Ellerton, Juliane Manitz, Luc Dirix, Galit Rosen
Publikováno v: Journal of Clinical Oncology. 37:428-428
428 Background: Avelumab is a human anti‒PD-L1 IgG1 antibody approved in the US, Canada, and Israel for the treatment of locally advanced or metastatic urothelial carcinoma (mUC) progressed after platinum chemotherapy. In the JAVELIN Solid Tumor st
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::51ab6cd99326284422de4aa94879586b
https://doi.org/10.1200/jco.2019.37.7_suppl.428
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje